
==== Front
Adv TherAdv TherAdvances in Therapy0741-238X1865-8652Springer Healthcare Cheshire 3115462699610.1007/s12325-019-00996-5CorrectionCorrection to: Immunogenic Yeast-Based Fermentation Product Reduces Allergic Rhinitis-Induced Nasal Congestion: A Randomized, Double-Blind, Placebo-Controlled Trial Moyad Mark A. moyad@umich.edu 1Robinson Larry E. 2Kittelsrud Julie M. 3Reeves Stuart G. 4Weaver Susan E. 3Guzman Aireen I. 5Bubak Mark E. 61 0000 0000 9081 2336grid.412590.bUniversity of Michigan Medical Center, Department of Urology, Ann Arbor, Michigan 48109-0330 USA 2 Vice President, Scientific Affairs, Embria Health Sciences, Ankeny, Iowa USA 3 0000 0004 0464 4831grid.414118.9Nurse Practitioner, Avera Research Institute, Sioux Falls, South Dakota USA 4 Director of Research and Development, Embria Health Sciences, Ankeny, Iowa USA 5 0000 0004 0464 4831grid.414118.9Statistical Consultant, Avera Research Institute, Sioux Falls, South Dakota USA 6 0000 0001 2293 1795grid.267169.dAssistant Professor, Allergy, Department of Internal Medicine, USD Sanford School of Medicine, Sioux Falls, South Dakota USA 1 6 2019 1 6 2019 2019 36 8 2191 2191 © The Author(s) 2019Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.issue-copyright-statement© Springer Healthcare Ltd., part of Springer Nature 2019
==== Body
Correction to: Adv Ther (2009) 26(8):795–804 10.1007/s12325-009-0057-y
The article “Immunogenic Yeast-Based Fermentation Product Reduces Allergic Rhinitis-Induced Nasal Congestion: A Randomized, Double-Blind, Placebo-Controlled Trial”, written by Mark A. Moyad, Larry E. Robinson, Julie M. Kittelsrud, Stuart G. Reeves, Susan E. Weaver, Aireen I. Guzman, Mark E. Bubak was originally published electronically on the publisher’s internet portal (currently Springer-Link) on 12 August, 2009 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on May, 2019. The Author(s) 2019 and the article is forthwith distributed under the terms of the Creative Commons Attribution [continuing for CC BY license].4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

